Esthesioneuroblastoma epidemiology and demographics
|
Esthesioneuroblastoma Microchapters | |
|
Diagnosis | |
|---|---|
|
Treatment | |
|
Case Studies | |
|
Esthesioneuroblastoma epidemiology and demographics On the Web | |
|
American Roentgen Ray Society Images of Esthesioneuroblastoma epidemiology and demographics | |
|
Esthesioneuroblastoma epidemiology and demographics in the news | |
|
Blogs on Esthesioneuroblastoma epidemiology and demographics | |
|
Risk calculators and risk factors for Esthesioneuroblastoma epidemiology and demographics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
The incidence of esthesioneuroblastoma is approximately 0.4 per 100,000 individuals worldwide. Esthesioneuroblastoma can present in a wide range of age groups; however, it is mostly noted in a bimodal distribution, occurring most frequently in the second and sixth decades of life. There is no racial predilection to the esthesioneuroblastoma.[1]
Epidemiology and Demographics
Esthesioneuroblastoma is noted in 4 out of 10 million individuals, accounting for 5% of sinonasal and 3% of intracranial tumors.[1]
Incidence
The incidence of esthesioneuroblastoma was estimated to be 0.4 cases per 100,000 individuals worldwide.
Age
Esthesioneuroblastoma commonly affects individuals in a wide range of age groups younger than 90/older than 3 (3-90) years of age. There exists a bimodal peak of occurrence in the third and sixth decades of life. The majority of cases of esthesioneuroblastoma occur in patients between 40 and 70 years of age; the median age at diagnosis is 53 years.It can present in a wide range of age groups; however, it is mostly noted in a bimodal distribution, occurring most frequently in the second and sixth decades of life.
Race
There is no racial predilection to the esthesioneuroblastoma.
Gender
There was a moderate male predominance with a 55:45 male:female ratio. Males are more commonly affected with esthesioneuroblastoma than females. The male to female ratio is approximately [1.2 > 1] to 1.[2][3][4][5]
References
- ↑ 1.0 1.1 Shirzadi, Ali S.; Drazin, Doniel G.; Strickland, Allison S.; Bannykh, Serguei I.; Johnson, J. Patrick (2013). "Vertebral Column Metastases from an Esthesioneuroblastoma: Chemotherapy, Radiation, and Resection for Recurrence with 15-Year Followup". Case Reports in Surgery. 2013: 1–8. doi:10.1155/2013/107315. ISSN 2090-6900.
- ↑ Ward PD, Heth JA, Thompson BG, Marentette LJ (2009). "Esthesioneuroblastoma: Results and Outcomes of a Single Institution's Experience". Skull Base. 19 (2): 133–40. doi:10.1055/s-0028-1096195. PMC 2671304. PMID 19721769.
- ↑ Diaz EM, Johnigan RH, Pero C, El-Naggar AK, Roberts DB, Barker JL; et al. (2005). "Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center". Head Neck. 27 (2): 138–49. doi:10.1002/hed.20127. PMID 15654688.
- ↑ Resto VA, Eisele DW, Forastiere A, Zahurak M, Lee DJ, Westra WH (2000). "Esthesioneuroblastoma: the Johns Hopkins experience". Head Neck. 22 (6): 550–8. PMID 10941155.
- ↑ Bachar G, Goldstein DP, Shah M, Tandon A, Ringash J, Pond G; et al. (2008). "Esthesioneuroblastoma: The Princess Margaret Hospital experience". Head Neck. 30 (12): 1607–14. doi:10.1002/hed.20920. PMID 18798301.